Tacrolimus Market Growth Forecast Through 2030: Market Size And Trends In 2026
Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.
Tacrolimus Market Expansion Outlook: What Revenue Opportunities Are Ahead?
The tacrolimus market has experienced substantial growth in recent years. Its size is anticipated to expand from $6.97 billion in 2025 to $7.39 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.0%. This historical growth can be attributed to an increase in organ transplantation procedures, the proven clinical effectiveness of tacrolimus, a rising prevalence of autoimmune and inflammatory conditions, improved success rates in transplants, and the development of healthcare infrastructure for transplant care.
The tacrolimus market is projected to experience substantial expansion over the upcoming years. Its value is anticipated to reach $9.06 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.2%. This projected growth during the forecast timeframe is primarily driven by factors such as the increasing volume of kidney and liver transplantation procedures, a surging need for affordable generic medications, the expanding application of the drug for off-label dermatological conditions, progress in monitoring immunosuppressive drugs, and the expansion of transplant initiatives within developing nations. Key trends observed throughout this period are expected to encompass a heightened demand for post-transplant immunosuppressive treatments, an increased utilization of tacrolimus in dermatological settings, a growing inclination towards generic immunosuppressant medications, improved long-term survival rates for organ transplant recipients, and a greater uptake of topical tacrolimus preparations.
Get A Free Sample Report With In-Depth Market Insights:
Tacrolimus Market Expansion Drivers: What’s Shaping Future Growth?
The tacrolimus market is projected to expand due to the increasing volume of organ transplant procedures. Organ transplantation involves surgically replacing a dysfunctional organ or tissue from a donor with one in a recipient. The demand for organ transplants is rising, driven by advancements in medical technology, improved surgical techniques, greater awareness of organ donation, and superior post-transplant care. Tacrolimus aids in organ transplantation by preventing the immune system from rejecting the new organ through the inhibition of T-cell activation and reduction of cytokine production. For example, the US-based non-profit Organ Procurement and Transplantation Network reported in January 2025 that kidney transplants saw a slight increase, reaching 27,759 in 2024, a 1.6 percent rise from 2023. Conversely, heart transplants remained largely consistent, with 4,572 procedures in 2024 compared to 4,545 in 2023. Consequently, the growing number of organ transplant procedures is fueling the tacrolimus market.
Tacrolimus Market Driver: The Rise In The Geriatric Population Driving The Growth Of The Market Due To Increased Need For Immune Modulation And Organ Rejection Management In Older Adults
The rising number of older adults is anticipated to stimulate the growth of the tacrolimus market. The geriatric population comprises individuals generally aged 65 and above, who often have distinct healthcare, social, and physiological requirements linked to aging. This increase is largely attributed to a higher life expectancy, allowing more people to live longer thanks to advancements in healthcare, better disease management, and improved living standards. Tacrolimus assists the geriatric population by modulating immune responses to prevent organ rejection and handle autoimmune conditions, thereby addressing their heightened vulnerability to immune-related issues. For instance, the UK Parliament’s House of Commons Library, a UK-based government administration, reported in July 2024 that 12.7 million people in the UK were aged 65 or over in 2022, making up 19% of the total population. This figure is predicted to climb to 22.1 million by 2072, constituting 27% of the population. Thus, the expanding geriatric population is propelling the growth of the tacrolimus market.
Tacrolimus Market Segment Outlook: Which Categories Are Growing Fastest?
The tacrolimus market covered in this report is segmented –
1) By Product Type: Tacrolimus Capsules And Tablets, Tacrolimus Injection, Tacrolimus Granules
2) By Application: Immunosuppression, Other Applications
3) By End User: Organ Transplant Centers, Hospitals, Clinics, Other End Users
Subsegments:
1) By Tacrolimus Capsules And Tablets: Oral Capsules, Oral Tablets
2) By Tacrolimus Injection: Injectable Solution, Injectable Powder
3) By Tacrolimus Granules: Oral Granules (For Suspension)
Tacrolimus Market Strategic Trends: What Defines The Next Growth Phase?
Key companies operating in the tacrolimus market are actively developing sophisticated medications, such as tacrolimus ointments, to fulfill the rising demand for innovative treatments for dermatological conditions and enhance patient care. Tacrolimus ointment serves as a topical treatment containing tacrolimus, an immunosuppressive agent primarily utilized for managing inflammatory skin conditions. For instance, in August 2023, Glenmark, an India-based pharmaceutical company, secured approval from the United States Food and Drug Administration (US FDA) for Tacrolimus Ointment 0.03%, which is the generic equivalent of Protopic Ointment 0.03%. Glenmark Pharmaceuticals will be responsible for distributing Tacrolimus Ointment, 0.03%, within the United States. This medication is prescribed for addressing moderate-to-severe atopic dermatitis, a skin condition marked by inflammation, redness, and itching.
Tacrolimus Market Leading Companies And Competitive Benchmarking
Major companies operating in the tacrolimus market are Astellas Pharma Inc, Novartis AG, Abbott Laboratories, Viatris Inc., Teva Pharmaceutical Industries Limited, Sandoz Inc, Sun Pharmaceutical Industries Limited, Dr. Reddy’s Laboratories Ltd., Cipla Limited, Lupin Limited, Hikma Pharmaceuticals, Biocon Ltd., Zydus Lifesciences Limited, Torrent Pharmaceuticals Limited, Alembic Pharmaceuticals Limited, Wockhardt Limited, Zhejiang Hisun Pharmaceutical Co. Ltd., Huadong Medicine Co Ltd, Glenmark Pharmaceuticals Ltd., Panacea Biotec
View The Full Tacrolimus Market Report:
Tacrolimus Market Geographic Analysis: Where Is Demand Accelerating Fastest?
North America was the largest region in the tacrolimus market in 2025. The regions covered in the tacrolimus market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
